We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Acro Biotech Highlights Expanded Toxicology and Rapid Diagnostic Portfolio

By LabMedica International staff writers
Posted on 18 Nov 2025

Acro Biotech is presenting its extensive product range at MEDICA 2025 that includes approved drugs of abuse tests, women’s health related rapid tests, cardiac markers, tumor markers, among others.

Exhibiting at booth C40-5 in Hall 3, the company invites attendees to explore a portfolio spanning drugs of abuse (DOA) testing, fluorescence immunoassay (FIA) panels, and urine analysis. More...

On display are new DOA rapid tests for Scopolamine (SCOP), Citalopram (CIT), and Fentanyl (FYL), reflecting demand for broader toxicology coverage in hospital and occupational health workflows.

For laboratory medicine applications, the company’s booth features FIA tests covering cardiac and endocrine markers, including Troponin I/Myoglobin/CK‑MB (creatine kinase‑MB), Prolactin, and Vitamin D. Instrumentation on display includes the Apoti Plus Fluorescence Immunoassay Analyzer (1 Channel) for benchtop use, the AcrMove Up Handheld Fluorescence Immunoassay Analyzer for mobile testing, and the Optilyte Plus Urine Analyzer to support routine urinalysis.

The lineup also includes the Urine Cup for Multi‑Drug Testing aimed at streamlined specimen collection and rapid screening. At the company's booth, specialists will provide live demonstrations and discuss implementation to align with laboratory and near‑patient workflows across emergency care, toxicology, and chronic disease monitoring.

Related Links:
Acro Biotech


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Clinical Informatics Platform
CLARION™
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.